The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Aciclovir     2-amino-9-(2- hydroxyethoxymethyl)-3H- purin...

Synonyms: Activir, Virolex, Zovirax, acyclovir, Avirax, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Vipral


Psychiatry related information on Vipral


High impact information on Vipral


Chemical compound and disease context of Vipral


Biological context of Vipral


Anatomical context of Vipral


Associations of Vipral with other chemical compounds

  • We conclude that acyclovir is better than vidarabine for the treatment of varicella-zoster infection in immunocompromised patients [28].
  • Thus, we conducted a controlled trial comparing long-term administration of ganciclovir with high-dose acyclovir for prevention of CMV infection and disease in liver transplant recipients [29].
  • The 3.3-kbp BamHI fragment containing most of the DNA polymerase gene from isolate 615.8 was purified and used to successfully transfer both acyclovir and foscarnet resistance [30].
  • Time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos; the risk ratios were 2.27 (95% Cl, 1.46 to 3.55) for total crusting and 2.07 (Cl, 1.26 to 3.38) for healing [31].
  • The resultant 100-fold increase in the ratio of the concentrations of acyclovir triphosphate to dGTP should facilitate the binding of the fraudulent nucleotide to its target enzyme, herpes virus-encoded DNA polymerase, and could account for the synergy between A1110U and acyclovir [32].
  • Mitochondrial toxicity is relatively low because acyclovir is activated only in infected cells by the promiscuous viral thymidine kinase and otherwise, mitochondrial toxicity would accumulate during long term treatment [33].

Gene context of Vipral


Analytical, diagnostic and therapeutic context of Vipral


  1. Acyclovir for herpes zoster. van den Broek, P.J., Stuyt, P.M., van der Meer, J.W. N. Engl. J. Med. (1994) [Pubmed]
  2. More on acyclovir for chickenpox. Duvic, M., Grossman, D. N. Engl. J. Med. (1994) [Pubmed]
  3. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. Kost, R.G., Hill, E.L., Tigges, M., Straus, S.E. N. Engl. J. Med. (1993) [Pubmed]
  4. Acyclovir to prevent cytomegalovirus infection in renal-graft recipients. Grundy, J.E., Griffiths, P.D. N. Engl. J. Med. (1989) [Pubmed]
  5. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. Whitley, R.J., Alford, C.A., Hirsch, M.S., Schooley, R.T., Luby, J.P., Aoki, F.Y., Hanley, D., Nahmias, A.J., Soong, S.J. N. Engl. J. Med. (1986) [Pubmed]
  6. Acyclovir in Creutzfeldt-Jakob disease. Newman, P.K. Lancet (1984) [Pubmed]
  7. Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. Prentice, H.G. J. Antimicrob. Chemother. (1983) [Pubmed]
  8. Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation. Shulman, H.M., Hinterberger, W. Bone Marrow Transplant. (1992) [Pubmed]
  9. Acute confusional state developing in a patient taking acyclovir: from the frying pan into the fire. Goor, Y., Goor, O., Cabili, S. Isr. Med. Assoc. J. (2002) [Pubmed]
  10. Psychological and psychosexual implications of herpes simplex virus infections. Mindel, A. Scandinavian journal of infectious diseases. Supplementum. (1996) [Pubmed]
  11. Acyclovir for recurrent herpes simplex virus ocular disease. Jabs, D.A. N. Engl. J. Med. (1998) [Pubmed]
  12. More on continuous-infusion acyclovir for severe varicella. Krolewiecki, A.J., Braffman, M. N. Engl. J. Med. (1997) [Pubmed]
  13. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. Wood, M.J., Johnson, R.W., McKendrick, M.W., Taylor, J., Mandal, B.K., Crooks, J. N. Engl. J. Med. (1994) [Pubmed]
  14. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. Whitley, R., Arvin, A., Prober, C., Burchett, S., Corey, L., Powell, D., Plotkin, S., Starr, S., Alford, C., Connor, J. N. Engl. J. Med. (1991) [Pubmed]
  15. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Whitley, R., Arvin, A., Prober, C., Corey, L., Burchett, S., Plotkin, S., Starr, S., Jacobs, R., Powell, D., Nahmias, A. N. Engl. J. Med. (1991) [Pubmed]
  16. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. Safrin, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J., Kessler, H.A., Landry, B., Mills, J. N. Engl. J. Med. (1991) [Pubmed]
  17. A trial of topical acyclovir in genital herpes simplex virus infections. Corey, L., Nahmias, A.J., Guinan, M.E., Benedetti, J.K., Critchlow, C.W., Holmes, K.K. N. Engl. J. Med. (1982) [Pubmed]
  18. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. Straus, S.E., Dale, J.K., Tobi, M., Lawley, T., Preble, O., Blaese, R.M., Hallahan, C., Henle, W. N. Engl. J. Med. (1988) [Pubmed]
  19. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. Bryson, Y.J., Dillon, M., Lovett, M., Acuna, G., Taylor, S., Cherry, J.D., Johnson, B.L., Wiesmeier, E., Growdon, W., Creagh-Kirk, T., Keeney, R. N. Engl. J. Med. (1983) [Pubmed]
  20. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. Straus, S.E., Takiff, H.E., Seidlin, M., Bachrach, S., Lininger, L., DiGiovanna, J.J., Western, K.A., Smith, H.A., Lehrman, S.N., Creagh-Kirk, T. N. Engl. J. Med. (1984) [Pubmed]
  21. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS. Bach, M.C. N. Engl. J. Med. (1987) [Pubmed]
  22. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Darby, G., Field, H.J., Salisbury, S.A. Nature (1981) [Pubmed]
  23. Prophylactic acyclovir in patients receiving bone marrow transplants. Trigg, M.E., Finlay, J.L., Sondel, P.M. N. Engl. J. Med. (1985) [Pubmed]
  24. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. Hanto, D.W., Frizzera, G., Gajl-Peczalska, K.J., Sakamoto, K., Purtilo, D.T., Balfour, H.H., Simmons, R.L., Najarian, J.S. N. Engl. J. Med. (1982) [Pubmed]
  25. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. Balfour, H.H., Chace, B.A., Stapleton, J.T., Simmons, R.L., Fryd, D.S. N. Engl. J. Med. (1989) [Pubmed]
  26. Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes. Koelle, D.M., Tigges, M.A., Burke, R.L., Symington, F.W., Riddell, S.R., Abbo, H., Corey, L. J. Clin. Invest. (1993) [Pubmed]
  27. Drugs five years later: acyclovir. Dorsky, D.I., Crumpacker, C.S. Ann. Intern. Med. (1987) [Pubmed]
  28. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. Shepp, D.H., Dandliker, P.S., Meyers, J.D. N. Engl. J. Med. (1986) [Pubmed]
  29. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Winston, D.J., Wirin, D., Shaked, A., Busuttil, R.W. Lancet (1995) [Pubmed]
  30. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Sacks, S.L., Wanklin, R.J., Reece, D.E., Hicks, K.A., Tyler, K.L., Coen, D.M. Ann. Intern. Med. (1989) [Pubmed]
  31. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Whitley, R.J., Weiss, H., Gnann, J.W., Tyring, S., Mertz, G.J., Pappas, P.G., Schleupner, C.J., Hayden, F., Wolf, J., Soong, S.J. Ann. Intern. Med. (1996) [Pubmed]
  32. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Spector, T., Harrington, J.A., Morrison, R.W., Lambe, C.U., Nelson, D.J., Averett, D.R., Biron, K., Furman, P.A. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  33. Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity. Hanes, J.W., Zhu, Y., Parris, D.S., Johnson, K.A. J. Biol. Chem. (2007) [Pubmed]
  34. Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Sugaya, S., Fujita, K., Kikuchi, A., Ueda, H., Takakuwa, K., Kodama, S., Tanaka, K. Hum. Gene Ther. (1996) [Pubmed]
  35. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. Landowski, C.P., Sun, D., Foster, D.R., Menon, S.S., Barnett, J.L., Welage, L.S., Ramachandran, C., Amidon, G.L. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  36. Inhibitory effects of IFN-gamma and acyclovir on the glioblastoma cell cycle. Kominsky, S.L., Subramaniam, P.S., Johnson, H.M., Torres, B.A. J. Interferon Cytokine Res. (2000) [Pubmed]
  37. Identification and analysis of the simian varicella virus thymidine kinase gene. Pumphrey, C.Y., Gray, W.L. Arch. Virol. (1996) [Pubmed]
  38. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. Cheon, J., Kim, H.K., Moon, D.G., Yoon, D.K., Cho, J.H., Koh, S.K. BJU international. (2000) [Pubmed]
  39. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. Meyers, J.D., Reed, E.C., Shepp, D.H., Thornquist, M., Dandliker, P.S., Vicary, C.A., Flournoy, N., Kirk, L.E., Kersey, J.H., Thomas, E.D. N. Engl. J. Med. (1988) [Pubmed]
  40. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. Gershon, A.A., Steinberg, S.P. N. Engl. J. Med. (1989) [Pubmed]
  41. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. Douglas, J.M., Critchlow, C., Benedetti, J., Mertz, G.J., Connor, J.D., Hintz, M.A., Fahnlander, A., Remington, M., Winter, C., Corey, L. N. Engl. J. Med. (1984) [Pubmed]
WikiGenes - Universities